|
Agenda | Short Course and Symposium Overview
Download the Preliminary Program
Short Courses (Sunday, May 11, 2008)
Short Course 1:
Metabolism-mediated Toxicity of Drugs: How to Design and Develop Safer Drugs
Chair: Sidney Nelson, University of Washington, Seattle, WA, USA
Structure-toxicity Relationships in Reactive Metabolite Mediated Drug Toxicities
Sidney Nelson, University of Washington, Seattle, WA, USA
An Integrated Approach to Minimizing the Potential for Metabolic Activation during Pharmaceutical Lead Optimization
Thomas Baillie, Merck & Co., West Point, PA, USA
Short Course 2:
P450 Enzymes: Novel Animal Models and Predication of In Vivo Metabolism
Chair: Xinxin Ding, SUNY at Albany, Albany, NY, USA
Applications of P450 Knockout and Transgenic Animal Models in Drug Metabolism and Toxicological Studies
Xinxin Ding, SUNY at Albany, Albany, NY, USA
The Use of In Vitro Metabolism Data to Predict Hepatic Clearance and Drug-drug Interactions in Humans
Scott Obach, Pfizer Inc., Groton, CT, USA
Short Course 3:
Drug Transporter and Its Role in Drug Discovery and Development
Chair: Yuichi Sugiyama, Tokyo University, Tokyo, Japan
Integration of In Vitro and In Vivo Data of Transporter Mediated Drug-drug Interaction and Pharmacogenomics
Yuichi Sugiyama, Tokyo University, Tokyo, Japan
Evaluation of Drug Transporters in Drug Discovery and Development
Cindy Xia, Millennium Pharmaceutical Inc., Cambridge, MA, USA
Short Course 4:
The Role of DMPK in Drug Development: Common Practice in Pharmaceutical Industry
Chair: June Ke, Novartis, East Hanover, NJ, USA
Design, Data Interpretation and Regulatory Consideration of Pharmacokinetics Studies in Preclinical and Clinical Development
June Ke, Novartis, East Hanover, NJ, USA
Drug Metabolism in Drug Development: From In Vitro Metabolite Profiling to Drug Registration
Donglu Zhang, Bristol-Myers Squibb, Princeton, NJ, USA
Welcome Reception Sponsor
Symposia (Monday, MAY 12, 2008)
PLENARY LECTURE I:
Fifty Years after the Discovery of Cytochrome P450: What Have We Learned and What Challenges Are Left Regarding Oxidative Metabolism?
F. Peter Guengerich, Vanderbilt University School of Medicine, Nashville, TN, USA
PLENARY LECTURE II:
Drug Transporters: From Bench to Bedside
Ken-ichi Inui, Kyoto University Hospital, Kyoto, Japan
SYMPOSIUM 1:
Current Topics in HTS Screening and Evaluation of DMPK Properties in Drug Discovery
Co-Chairs: Sonia De Morais, Pfizer, Groton , CT, USA
Toshihiko Ikeda, Association of Promoting Drug Development, Yokohama, Japan
Industrial Perspective of Blood-tissue Barrier in Drug Discovery and Development
Jiunn Lin, Merck Co.,West Point, PA, USA
A Novel Model for the Prediction of Drug-drug Interactions without Using the [I] / Ki ratio
Chuang Lu, Millennium Pharmaceuticals, Cambridge, MA, USA
Integration of ADME/PK into Hit-to-Lead Drug Discovery
Jing Lin, Pfizer, Groton, CT, USA
In Cerebro Prediction of DMPK Properties
Toshihiko Ikeda, Association of Promoting Drug Development, Yokohama, Japan
SYMPOSIUM 2:
Regulatory and Scientific Considerations of Drug Metabolism and Drug Interaction Studies
Co-Chairs: Jiaqi Xu, Chinese State Food and Drug Administration, Beijing, China
Kyung Won Seo, Korea Food and Drug Administration, Korea
Current Status on Reviewing Drug-drug Interaction of Innovative Therapeutics in China
Jiaqi Xu, Chinese State Food and Drug Administration, Beijing, China
Review Point of Drug Interaction Studies
Kyung Won Seo, Korea Food and Drug Administration, Korea
Pharmacokinetic Consideration on Ethnic Bridging Evaluation in Taiwan
Chen-Hsi Chou, National Cheng Kung University, Tainan, Taiwan
Scientific Perspectives on Evaluating Metabolic Interactions during Innovation of Therapeutics
Shiewmei Huang, United States Food and Drug Administration, Rockbville, MD, USA
PMDA's Challenge to Encourage Global Clinical Development Including Asian Study
Kazuhiko Mori, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan
Roundtable Discussion(with lunch) 
Regulatory and Scientific Considerations of Drug Metabolism and Drug Interaction Studies
Novel Approaches, Using UPLC-MS/MS and Chemically Intelligent Software to Fully Profile Metabolic Biotransformations of New Chemical Entities
John P. Shockcor, Director of Metabolic profiling Business Development, Waters Corporation
SYMPOSIUM 3:
Inhibition and Reaction Phenotyping of Transporters: Implications in Drug Discovery and Development
Co-Chairs: Ikumi Tamai, Tokyo University of Science, Chiba, Japan
Hequn Yin, Shanghai R&D Center, Novartis
Drug-induced Inhibition and Activation of Physiological Transporters
Ikumi Tamai, Tokyo University of Sciences, Chiba, Japan
Temporal Dependency in MDR1 Function in the Blood Brain Barrier during Experimental Diabetes
Suk-Jae Chung, Seoul National University, Seoul, Korea
Role of Membrane Transporters in the Safety Profiles of Drugs
Edmond Lee, National University of Singapore, Singapore
SYMPOSIUM 4:
Advances in the Applications of LC/MS and Biomarker to Metabolite Profiling and Bioanalysis
Co-Chairs: Dafang Zhong, Shanghai Institute of Materia Medica, Shanghai, China Mingshe Zhu, Bristol-Myers Squibb, Princeton, NJ, USA
Identification of Some Uncommon Pathways in Drug Metabolism with LC/MS/MS
Dafang Zhong, Shanghai Institute of Materia Medica, Shanghai, China
Use of Bioassay to Profile Pharmacokinetics of Natural and Biotechnological Drug Candidates
Guozhu Han, Dalian Medical University, Dalian, China
High Throughput Screening of Reactive Metabolites Using Hybrid Mass Spectrometers
Mingshe Zhu, Bristol Myers Squibb, Princeton, NJ, USA
SYMPOSIUM 5:
Receptor- and/or Transporter-mediated Drug Targeting
Chair: Chang-Koo Shim, Seoul National University, Seoul, Korea
Receptor –mediated Delivery of Drugs, Proteins and Genes
Makiya Nishikawa, Kyoto University, Kyoto, Japan
Use of Pharmaceutical Excipients in Enhancing GI Absorption by Inhibiting Efflux Transporters
Mariko Morishita, Department of Pharmaceutics, Hoshi University, Tokyo, Japan
Tumor Targeting of Anticancer Drug via Surface Modified Nanoparticles
Chang-Koo Shim, Seoul National University, Seoul, Korea
SYMPOSIUM 6:
Role of Phase II Conjugations in Drug Metabolism and Disposition
Chair: Su Zeng, Zhejiang University, Hangzhou, China
Michelle Minxia He, Eli Lilly & Co., Indianapolis, IN, USA
Stereoselectivity in Chiral Drug Glucuronidation with UGTs
Su Zeng , Zhejiang University, Hangzhou, China
The Correlation between Therapeutic Outcome of Anti-tuberculosis and Genetic Polymorphism of NAT 2 in Taiwan Aboriginals
Li-Jiuan Shen, National Taiwan University, Taipei, Taiwan
Probing UDP-glucuronosyltransferase Structure-function
John Miners, Flinders Medical Centre and Flinders University, Adelaide, Australia
TUESDAY, MAY 13, 2008
Symposia (Tuesday, MAY 13, 2008)
SYMPOSIUM 7:
Pharmacogenomics in Target Validation and Drug Therapy
Chair: Honghao Zhou, Central South University, Changsha, China
Junyan Hong, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ, USA
Pharmacogenetics of Herb-drug Interactions Induced by Drug Metabolism Enzymes
Honghao Zhou, Central South University, Changsha, China
Genetic Variation of P450 Reductase as a Potential Biomarker to Predict Anti-cancer Drug Response
Jun-Yan Hong, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ, USA
Pharmacogenomics of Anticoagulant and Antiplatelet Drugs
Jae-Gook Shin, Inje University, Busan, Korea
Genetic Polymorphism of Drug Metabolizing Enzymes in Thais
Wichittra Tassaneeyakul , Khon Kaen University , Khon Kaen, Thailand
SYMPOSIUM 8:
Nuclear Receptor and Transcriptional Factor
Chair: Yasushi Yamazoe, Tohoku University, Graduate School of Pharmaceutical Sciences, Sendai, Japan
Involvement of Plural Nuclear Receptors in Drug Metabolizing Gene Activations
Yasushi Yamazoe, Tohoku University, Graduate School of Pharmaceutical Sciences, Sendai, Japan
Pharmacogenomics of Nuclear Receptors in Relation to Drug Disposition
Sang-Seop Lee, Inje University, Busan, Korea
Activation of ARNT/HIF-1 Signal Pathway Up-regulates Epidermal Growth Factor-induced Cyclooxygenase-2 Gene Expression
Ben-Kuen Chen, National Cheng Kung University, Tainan, Taiwan
Transcriptional Regulation of Drug Metabolising Enzymes
Peter Mackenzie, Flinders Medical Centre and Flinders University, Adelaide , Australia
Work Lunch 
SYMPOSIUM 9:
Contemporary DMPK Issues in the Development of Herbal Medicine
Co-Chairs: Guangji Wang, Chinese Pharmaceutical University, Nanjing, China
Oliver Yoa-Pu Hu, National Defense Medical Center, Taipei, Taiwan
Sugn Yeon Kim, Wonkwang University, Iksan Chonbuk, Korea
Chuan Li, Shanghai Institute of Mateira Medica, Shanghai, China
Challenges in Drug Metabolism and Pharmacokinetics for Research on Traditional Chinese Medicines
Changxiao Liu, Tianjin Institute of Pharmaceutical Research, Tianjin, China
Modernized Traditional Chinese Medicine Significantly Inhibit Hepatic Enzymes: Address to the Risk of Herb-Drug Interactions
Oliver Yoa-Pu Hu, National Defense Medical Center, Taipei, Taiwan
Application of Innovative Technology and Method into Pharmacokinetic Research of Herb Medicines
Guangji Wang, Chinese Pharmaceutical University, Nanjing, China
Herb-drug Interactions: Where are they from?
Bingfang Yan, University of Rhode Island, Kingston, RI, USA
Role of Pharmacokinetic Information in Botanical Drug Products
Sung Yeon Kim, Wonkwang University, Iksan Chonbuk, Korea
Bioanalytical Measurement of Herbal Compounds and Identification of PK Markers for Herbal Remedies
Chuan Li, Shanghai Institute of Materia Medica, Shanghai, China
Symposium 10:
Predicting GI Absorption and Bioavailability: Dissolution, Permeability, Enzyme and Transporters
Chair: Shinji Yamashita, Setsunan University, Osaka, Japan
Yan Li, Institute of Materia Medica, Beijing, China
Prediction of Oral Absorption of Drugs in Human
Shinji Yamashita, Setsunan University, Osaka, Japan
Effect of CYP3A/P-gp on the Absorption and Metabolism of New Drugs
Yan Li, Institute of Materia Medica, Chinese Academy of Medical Sciences, Beijing, China
How Does Genetic Polymorphism of Cytochrome P450’s Affect Oral Bioavailability of a High Clearance Drug
Jin-ding Huang, National Cheng Kung University, Tainan, Taiwan
Symposium 11:
Prediction of Adverse Drug Reactions: Detection of Reactive Metabolites and Use of Omics (genomics, proteomics and metabonomics)
Chair: Takahiko Baba, Shionogi & Co, Ltd. Osaka, Japan
Haijun Dong, Roche, Shanghai, China
Evaluation of Toxicity in Early Stage of Drug Development
Takahiko Baba, Shionogi & Co, Ltd. Osaka, Japan
Genetic Susceptibility to Severe Adverse Drug Reactions
Yuang-Tsong Chen , Academica Sinica, Taipei, Taiwan
Assessment of Drug Safety Based on Toxicogenomic Information
Rashmi Barbhaiya, Advinus Therapeutics Pvt Ltd, Bangalore, India
Awards Presentation 
Announcement of future meetings
Co-Chairs: Honghao Zhou, Yuichi Sugiyama, Zhuohan Hu |
